Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q3 2025 value amounting to -$91.6 million.

  • Whitehawk Therapeutics' Cash from Investing Activities fell 190190.76% to -$91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 4797.05%. This contributed to the annual value of $25.2 million for FY2024, which is 6971.13% down from last year.
  • Per Whitehawk Therapeutics' latest filing, its Cash from Investing Activities stood at -$91.6 million for Q3 2025, which was down 190190.76% from -$28.8 million recorded in Q2 2025.
  • Whitehawk Therapeutics' 5-year Cash from Investing Activities high stood at $115.5 million for Q1 2025, and its period low was -$91.6 million during Q3 2025.
  • Over the past 5 years, Whitehawk Therapeutics' median Cash from Investing Activities value was $3.6 million (recorded in 2023), while the average stood at -$242529.4.
  • In the last 5 years, Whitehawk Therapeutics' Cash from Investing Activities tumbled by 18333260.87% in 2022 and then surged by 7109565.22% in 2023.
  • Whitehawk Therapeutics' Cash from Investing Activities (Quarter) stood at -$46000.0 in 2021, then tumbled by 183332.61% to -$84.4 million in 2022, then surged by 104.32% to $3.6 million in 2023, then soared by 259.91% to $13.1 million in 2024, then plummeted by 797.69% to -$91.6 million in 2025.
  • Its Cash from Investing Activities was -$91.6 million in Q3 2025, compared to -$28.8 million in Q2 2025 and $115.5 million in Q1 2025.